Attached files
file | filename |
---|---|
EX-10 - EXHIBIT 10.1 - VistaGen Therapeutics, Inc. | ex10-1.htm |
8-K - CURRENT REPORT - VistaGen Therapeutics, Inc. | vtgn8k_apr232021.htm |
Exhibit 99.1
VistaGen Therapeutics Announces Appointment of
Joanne Curley, Ph.D. to its Board of
Directors
Dr. Curley
brings extensive pharmaceutical industry experience in product
development, commercialization and operations as VistaGen advances
late-stage development of its product candidates for anxiety and
depression disorders
SOUTH
SAN FRANCISCO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- VistaGen
Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company
committed to developing a new generation of medicines with the
potential to go beyond the current standard of care for anxiety,
depression and other central nervous system (“CNS”)
disorders, today announced the appointment of Joanne Curley, Ph.D.
to its Board of Directors (“Board”). Following the
appointment of Dr. Curley, VistaGen’s Board will be comprised
of seven directors.
“Joanne
brings more than 25 years of pharmaceutical industry experience
across numerous key operational and therapeutic areas,” said
Shawn Singh, Chief Executive Officer of VistaGen. “Her track
record of propelling seven products from early development through
regulatory approval is impressive and reflects her extensive
experience and understanding of the entire life cycle of drug
development. As we expand our business and pursue our mission to
improve mental health and well-being for individuals in the U.S.
and abroad, her tremendous leadership, creativity and expertise
will be invaluable to VistaGen.”
Dr.
Curley is currently the Chief Development Officer at Vera
Therapeutics, Inc. Prior to joining Vera, Dr. Curley spent 15 years
with Gilead Sciences, during which time the anti-viral portfolio
grew from four to seventeen commercial products. While at Gilead,
Dr Curley led Project and Portfolio Management with oversight of
the development pipeline across four therapeutic areas and was
responsible for research and development governance. Before Gilead,
Dr. Curley worked as an aerosol formulation scientist and
subsequently as a project leader at Nektar Therapeutics. She
received a BSc in Physics and Chemistry from Trinity College,
Ireland, a Ph.D. in Polymer Science and Engineering from the
University of Massachusetts, Amherst and completed a post-doctorate
at Massachusetts Institute of Technology and Harvard Medical
School, focused on long-acting biodegradable
formulations.
About VistaGen
VistaGen Therapeutics is a
biopharmaceutical company committed to developing and
commercializing innovative medicines with the potential to go
beyond the current standard of care for anxiety, depression, and
other CNS disorders. Each of VistaGen's three drug candidates has a
differentiated potential mechanism of action, has been
well-tolerated in all clinical studies to date and has therapeutic
potential in multiple CNS markets. For more information, please
visit www.VistaGen.com and connect with VistaGen on
Twitter, LinkedIn, and Facebook.
Forward
Looking Statements
This
press release contains certain forward-looking statements within
the meaning of the federal securities laws. These forward-looking
statements involve known and unknown risks that are difficult to
predict and include all matters that are not historical facts. In
some cases, you can identify forward-looking statements by the use
of words such as “may,” “could,”
“expect,” “project,” “outlook,”
“strategy,” “intend,” “plan,”
“seek,” “anticipate,”
“believe,” “estimate,”
“predict,” “potential,”
“strive,” “goal,” “continue,”
“likely,” “will,” “would” and
variations of these terms and similar expressions, or the negative
of these terms or similar expressions. Such forward-looking
statements are necessarily based upon estimates and assumptions
that, while considered reasonable by us and our management, are
inherently uncertain. Our actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include,
without limitation, risks and uncertainties relating to delays in
launching and/or conducting our planned clinical trials, including
delays due to the impact of the COVID-19 pandemic; fluctuating
costs of materials and other resources required to conduct our
planned clinical and non-clinical trials; continued uncertainty
with respect to the COVID-19 pandemic; market conditions; the
impact of general economic, industry or political conditions in the
United States or internationally; adverse healthcare reforms and
changes of laws and regulations; manufacturing and marketing risks,
including risks related to the COVID-19 pandemic, which may
include, but are not limited to, unavailability of or delays in
delivery of raw materials for manufacture of our CNS drug
candidates and difficulty in initiating or conducting clinical
trials; inadequate and/or untimely supply of one or more of our CNS
drug candidates to meet demand; entry of competitive products; and
other technical and unexpected hurdles in the development,
manufacture and commercialization of our CNS drug candidates; and
the risks more fully discussed in the section entitled "Risk
Factors" in our most recent Annual Report on Form 10-K for the year
ended March 31, 2020, and in our most recent Quarterly Report on
Form 10-Q for the quarter ended December 31, 2020, as well as
discussions of potential risks, uncertainties, and other important
factors in our other filings with the U.S. Securities and Exchange
Commission (SEC). Our SEC filings are available on the SEC’s
website at www.sec.gov. You should not place undue reliance on
these forward-looking statements, which apply only as of the date
of this press release and should not be relied upon as representing
our views as of any subsequent date. We explicitly disclaim any
obligation to update any forward-looking statements, other than as
may be required by law. If we do update one or more forward-looking
statements, no inference should be made that we will make
additional updates with respect to those or other forward-looking
statements.
VistaGen Company Contacts
Mark
McPartland / Mark Flather
VistaGen
Therapeutics
Phone:
(650) 577-3606
Email:
IR@vistagen.com